According to a recent LinkedIn post from Plantible Foods, the company has received an FDA “No Questions” letter for its Rubi Protein, an isolated RuBisCO protein ingredient intended for food applications. The post suggests this represents the first FDA acknowledgment of isolated RuBisCO for such uses and frames it as both a regulatory and industry milestone.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post highlights that this regulatory clearance may open the path for large-scale commercialization of Rubi Protein as a functional, bioavailable protein designed to support improved taste, nutrition, and sustainability in food products. For investors, this could indicate progress toward revenue generation via new B2B ingredient supply agreements, though commercial uptake will depend on customer adoption, pricing, and competitive positioning in the alternative protein market.
As described in the post, Plantible credits regulatory partners, customers, and its internal team, and indicates an intention to continue working with customers and collaborators to bring products containing Rubi Protein to market. If the ingredient gains traction with major food manufacturers, this regulatory step could strengthen Plantible’s strategic position in the protein-ingredient segment and potentially enhance its valuation prospects within the broader food-innovation and sustainable-protein space.